Effect of long acting insulin supplementation on diabetic nephropathy in wistar rats

Indian Journal of Experimental Biology

Volumn 50, Issue 12, 2012, Pages 867-874

  Michael, Shiju Thomas ^a   Ganesh, Rajesh Nachiappa ^b   Viswanathan, Pragasam ^a  

^a VIT UNIVERSITY   (India)

^b JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Diabetic nephropathy; Glargine; Long acting insulin; Rat model; Streptozotocin

Indexed keywords

CREATININE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONG ACTING INSULIN; MITOGEN ACTIVATED PROTEIN KINASE 3; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ALBUMINURIA; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; KIDNEY; MALE; METABOLISM; PATHOLOGY; RAT; TIME; URINE; WISTAR RAT;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; INSULIN, LONG-ACTING; KIDNEY; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; RATS; RATS, WISTAR; STREPTOZOCIN; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84871547190     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parving H H, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, Lauritzen M, Hougaard P and Lauritzen E, Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy with insulin dependent diabetes, Br Med J, 296 (1988) 156.
2. Nicholas R L, Diabetic kidney disease: Preventing dialysis and transplantation, Clin Diabetes, 21 (2003) 55.
3. Nobrega M A, Fleming S, Roman R J, Shiozawa M, Schlick N, Lazar J and Jacob H J, Initial characterization of a rat model of diabetic nephropathy, Diabetes, 53 (2004) 735.
4. Yokozawa T, Nakagawa T, Wakaki K and Koizumi F, Animal model of diabetic nephropathy, Exp Toxicol Pathol, 53 (2001) 359.
5. Brownlee M, Biochemistry and molecular cell biology of diabetic complications, Nature, 414 (2001) 813.
6. Ruster C and Wolf G, Models of diabetic nephropathy, Drug Discov Today: Disease models, 10 (2010) 35.
7. Marliss E B, Nakhooda A F and Poussier P, Clinical forms and natural history of the diabetic syndrome, insulin and glucagon secretion in the BB rat, Metabolism, 32 (1983) 11.
8. Schmitz P G, O'Donell M P, Kasiske B L, Katz S A and Keane W F, Renal injury in obese zucker rats: glomerular hemodynamic alterations and effects of enalapril, Am J Physiol, 263 (1992) 496.
9. Velasquez M T, Abraham A A, Kimmel P L, Farkas-Szallasi T and Michaelis O E, Diabetic glomerulopathy in the SHR/Ncorpulent rat: role of dietary carbohydrate in a model of NIDDM, Diabetologia, 38 (1995) 31.
10. Janssen U, Phillips A O and Floege J, Rodent models of nephropathy associated with type-2 diabetes, J Nephrol, 12 (1999) 159.
11. Popov D, Simionescu M and Shepherd P R, Saturated fat induces moderate and severe glomerulosclerosis in hamster, Diabetologia, 46 (2003) 1408.
12. Wolf G, After all those fat: Renal consequence of obesity, Nephrol Dial Transplant, 18 (2003) 2471.
13. Riley S G, Steadman R, Williams J D, Floege J and Phillips A O, Augmentation of kidney injury by basic fibroblast growth factor or platelet-derived growth factor does not induce progressive diabetic nephropathy in the Goto-Kakizaki model of non-insulin-dependent diabetes, J Lab Clin Med, 134 (1999) 304.
14. Tesch G H and Allen T J, Rodent models of streptozotocin induced diabetic nephropathy, Nephrology, 12 (2007) 261.
15. Tuncdemir M and Ozturk M, The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin induced diabetic nephropathy, Acta Histochem, 113 (2011) 826.
16. Makino H, Tanaka I, Mukoyama M, Sugawara A, Mori K, Muro S, Suganami T, Yahata K, Ishibashi S, Maruyama T, Narumiya S and Nakao K, Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP-1 selective antagonist, J Am Soc Nephrol, 13 (2002) 1757.
17. Tay Y C, Wang Y, Kairaitis L, Rangan G K, Zhang C and Harris D C, Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int, 68 (2005) 391.
18. Kraynak A R, Storer R D and Jensen R D, Extent and persistence of streptozotocin induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays, Toxicol App Pharmacol, 135 (1995) 279.
19. Kelly D J, Wilkinson-Berka J L, Allen T J, Cooper M E and Skinner S L, A new model of diabetic nephropathy with progressive renal impairment in the transgenic rat, Kidney Int, 54 (1998) 343.
20. Li X, Cui X, Sun X, Li X, Zhu Q and Li W, Mangiferin prevents diabetic nephropathy progression in Streptozotocin induced diabetic rats, Phytother Res, 24 (2011) 893
21. Davis B J, Johnston C I, Burrell L M, Burns W C, Kubota E, Cao Z, Cooper M E and Allen T J, Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy, Diabetologia, 46 (2003) 961
22. Gendler S, Proteins, Clinical chemistry: Theory, analysis and correlation (Toranto) 1984, 1268.
23. Crocker C L, Rapid determination of urine urea nitrogen in serum or plasma without deproteination, Am J Med Tech, 33 (1967) 361.
24. Farrell S C and Bailey M P, Measurement of creatinine in peritoneal dialysis fluid, Ann Clin Biochem, 28 (1991) 624.
25. Ohtake K, Ishiyama Y, Uchinda H, Muraki E and Kobayashi J, Dietary nitrite inhibits early glomerular injury in Streptozotocin induced diabetic nephropathy in rats, Nitric oxide, 17 (2007) 75.
26. Rosario R F and Prabhakar S, Lipids and diabetic nephropathy, Curr Diab Rep, 6 (2006) 455.
27. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F and Egido J, Activation of nucleation factor κB in tubular epithelial cells of rats with intense proteinuria, role of angiotensin II and endothelin-1, Hypertension, 37 (2001) 1171.
28. Bierhaus A, Humpert P M, Morcos M, Wendt T, Chavakis T, Arnold B, Stern D M and Mawroth P P, Understanding RAGE, the receptor for advanced glycation end products, J Mol Med, 83 (2005) 876.
29. Ramasamy R, Vannucci S J, Yan S S D, Herold K, Yan S F and Schmidt A M, Advanced glycation end products and RAGE: A common threat in aging, diabetes, neurodegeneration and inflammation, Glycobiology, 15 (2005) 16.
30. Bucciarelli L G, Wendt T, Rong L, Lalla E, Hofmann M A, Goova M T, Taquchi A, Yan SF, Yan S D, Stern D M and Schmidt A M, RAGE is a multiligand receptor of the Immunoglobin superfamily: implications for homeostasis and chronic disease, Cell Mol Life Sci, 59 (2002) 1117.
31. Lappas M, Permezel M and Rice G E, Leptin and adiponectin stimulate the release of pro-inflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via NF-κB, PPAR-gamma and ERK 1/2, Endocrinology, 146 (2005) 3334.
32. Jung H, Yoon B, Jun J, Kim M, Kim Y and Kim C, Differential activation of mitogen activated protein kinase and nuclear factor-κB in lipopolysaccharide treated term and preterm amnion cells, Virchows Arch, 447 (2005) 45.
33. Chen S and Ziyadeh F N, Vascular endothelial growth factor and diabetic nephropathy, Curr Diab Rep, 8 (2008) 470.
34. Hovind P, Tarnow L, Oestergaard P B and Parving H H, Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy, Kidney Int Suppl, 75 (2000) S56.
35. Cellier E, Mage M, Duchene J, Pecher C, Couture R, Bascands J L and Girolami J P, Bradykinin reduces growth factor induced glomerular ERK 1/2 phosphorylation, Am J Physiol Renal Physiol, 284 (2003) F282.
36. Toyoda M, Suzuki D, Homma M, Uehara G, Sakai T, Umezono T and Sakai H. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy, Kidney Int, 66 (2004) 1107.
37. Chen K H, Hung C C, Hsu H H, Jing Y H, Yang C W and Chen J K, Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK 1/2 signaling in Streptozotocin induced diabetic rats, Chem Biol Interact, 190 (2011) 45.
38. Guijarro C and Egido J, Transcription factor kappa B (NF-κB) in renal disease, Kidney Int, 59 (2001) 415.
39. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F and Egido J, Activation of nucleation factor κB in tubular epithelial cells of rats with intense proteinuria, role of angiotensin II and endothelin-1, Hypertension, 37 (2001) 1171.
40. Li L, Emmett N, Mann D and Zhao X, Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor -κB and transforming growth factor-β1/Smad3 in diabetic nephropathy, Exp Biol Med, 235 (2010) 383.
41. Miquel-Carrasco JL, Zambrano S, Blanca AJ, Mate A and Vazquez CM, Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-κB, J Inflamm, 12 (2010) 21.
42. Mezzano S, Aros C, Droquett A, Burgos M E, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, Egido J, NF-κB activation and over expression of regulated genes in human diabetic nephropathy, Nephrol Dial Transplant, 10 (2004) 2505.